GSA 10Smo receptor agonist; induces differentiation of mesenchymal progenitor cells into osteoblasts CAS# 300833-95-8 |
- Adefovir Dipivoxil
Catalog No.:BCC5025
CAS No.:142340-99-6
- Merimepodib
Catalog No.:BCC4128
CAS No.:198821-22-6
- Telbivudine
Catalog No.:BCC3862
CAS No.:3424-98-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 300833-95-8 | SDF | Download SDF |
| PubChem ID | 54683103 | Appearance | Powder |
| Formula | C26H30N2O5 | M.Wt | 450.53 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 5 mM in DMSO with gentle warming | ||
| Chemical Name | propyl 4-[(1-hexyl-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]benzoate | ||
| SMILES | CCCCCCN1C2=CC=CC=C2C(=C(C1=O)C(=O)NC3=CC=C(C=C3)C(=O)OCCC)O | ||
| Standard InChIKey | MDLUYYGRCGDKGL-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C26H30N2O5/c1-3-5-6-9-16-28-21-11-8-7-10-20(21)23(29)22(25(28)31)24(30)27-19-14-12-18(13-15-19)26(32)33-17-4-2/h7-8,10-15,29H,3-6,9,16-17H2,1-2H3,(H,27,30) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Smoothened (Smo) receptor agonist (EC50 = 1.2 μM). Does not recognize the classic cyclopamine binding site. Does not promote Smo translocation to the primary cilium; is strongly potentiated by forskolin and cholera toxin. Promotes differentiation of multipotent mesenchymal progenitor cells into osteoblasts. |
GSA 10 Dilution Calculator
GSA 10 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2196 mL | 11.098 mL | 22.1961 mL | 44.3922 mL | 55.4902 mL |
| 5 mM | 0.4439 mL | 2.2196 mL | 4.4392 mL | 8.8784 mL | 11.098 mL |
| 10 mM | 0.222 mL | 1.1098 mL | 2.2196 mL | 4.4392 mL | 5.549 mL |
| 50 mM | 0.0444 mL | 0.222 mL | 0.4439 mL | 0.8878 mL | 1.1098 mL |
| 100 mM | 0.0222 mL | 0.111 mL | 0.222 mL | 0.4439 mL | 0.5549 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ciluprevir (BILN-2061)
Catalog No.:BCC1482
CAS No.:300832-84-2
- RS 504393
Catalog No.:BCC1910
CAS No.:300816-15-3
- TG003
Catalog No.:BCC4416
CAS No.:300801-52-9
- BMS 309403
Catalog No.:BCC8046
CAS No.:300657-03-8
- HMBA Linker
Catalog No.:BCC2831
CAS No.:3006-96-0
- SKF 77434 hydrobromide
Catalog No.:BCC7144
CAS No.:300561-58-4
- Dehydrocorydalin
Catalog No.:BCN2474
CAS No.:30045-16-0
- Boc-Asn-ol
Catalog No.:BCC2587
CAS No.:30044-67-8
- Ro 28-1675
Catalog No.:BCC4124
CAS No.:300353-13-3
- Diphyllin O-glucoside
Catalog No.:BCN8065
CAS No.:30021-77-3
- HEAT hydrochloride
Catalog No.:BCC6683
CAS No.:30007-39-7
- Isoline
Catalog No.:BCN2063
CAS No.:30000-36-3
- 4-CMTB
Catalog No.:BCC6250
CAS No.:300851-67-6
- Methyl Linolenate
Catalog No.:BCN8318
CAS No.:301-00-8
- Oleamide
Catalog No.:BCC6827
CAS No.:301-02-0
- Robinin
Catalog No.:BCN5208
CAS No.:301-19-9
- Malvidin-3-O-galactoside chloride
Catalog No.:BCN3030
CAS No.:30113-37-2
- Tianeptine sodium
Catalog No.:BCC2506
CAS No.:30123-17-2
- TCS 359
Catalog No.:BCC1183
CAS No.:301305-73-7
- CH 223191
Catalog No.:BCC3896
CAS No.:301326-22-7
- P7C3
Catalog No.:BCC6524
CAS No.:301353-96-8
- H-Val-NH2.HCl
Catalog No.:BCC3144
CAS No.:3014-80-0
- Seneganolide
Catalog No.:BCN5209
CAS No.:301530-12-1
- Compstatin control peptide
Catalog No.:BCC6067
CAS No.:301544-78-5
Discovery, molecular and pharmacological characterization of GSA-10, a novel small-molecule positive modulator of Smoothened.[Pubmed:23448715]
Mol Pharmacol. 2013 May;83(5):1020-9.
Activation of the Smoothened (Smo) receptor mediates Hedgehog (Hh) signaling. Hh inhibitors are in clinical trials for cancer, and small-molecule Smo agonists may have therapeutic interests in regenerative medicine. Here, we have generated and validated a pharmacophoric model for Smo agonists and used this model for the virtual screening of a library of commercially available compounds. Among the 20 top-scoring ligands, we have identified and characterized a novel quinolinecarboxamide derivative, propyl 4-(1-hexyl-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamido) benzoate, (GSA-10), as a Smo agonist. GSA-10 fits to the agonist pharmacophoric model with two hydrogen bond acceptor groups and four hydrophobic regions. Using pharmacological, biochemical, and molecular approaches, we provide compelling evidence that GSA-10 acts at Smo to promote the differentiation of multipotent mesenchymal progenitor cells into osteoblasts. However, this molecule does not display the hallmarks of reference Smo agonists. Remarkably, GSA-10 does not recognize the classic bodipy-cyclopamine binding site. Its effect on cell differentiation is inhibited by Smo antagonists, such as MRT-83, SANT-1, LDE225, and M25 in the nanomolar range, by GDC-0449 in the micromolar range, but not by cyclopamine and CUR61414. Thus, GSA-10 allows the pharmacological characterization of a novel Smo active site, which is notably not targeted to the primary cilium and strongly potentiated by forskolin and cholera toxin. GSA-10 belongs to a new class of Smo agonists and will be helpful for dissecting Hh mechanism of action, with important implications in physiology and in therapy.
